Condition: Influenza · Influenza, Human · Sponsor: University of Oxford
This trial will use a previously validated platform, to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated influenza, to determine in-vivo antiviral activity. In this randomised, open-label, controlled, group sequential, adaptive, platform trial, we will compare the performance of available influenza antivirals, and those with potential activity, relative to the control (no treatment) and each other. AD ASTRA study is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator
This description comes directly from the study's public registry record.
William Schilling, MD · +662 203 6333 · william@tropmedres.ac
Nicholas J White, Prof · +662 203 6333 · nickw@tropmedres.ac
Always discuss trial participation with your own doctor first.
| Universidade Federal de Minas Gerais | Minas Gerais, Brazil | Recruiting |
| Laos-Oxford-Mahosot Wellcome Trust Research unit | Vientiane, Laos | Recruiting |
| Sukraraj Tropical & Infectious Disease Hospital | Kathmandu, Nepal | Recruiting |
| Faculty of Tropical Medicine, Mahidol University | Bangkok, Thailand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05648448